IP Library Granted Patent US 10,166,177
Granted Patent B2
US 10,166,177 · App. 14/503,076 · Granted Jan 1, 2019

Silk protein fragment compositions and articles manufactured therefrom

Inventors: Gregory H. Altman (Arlington, MA); Rebecca L. Lacouture (Arlington, MA); Rachel Lee Dow (Medford, MA); Rachel M. Lind (Somers, NY); Dylan S. Haas (Yorktown Heights, NY)
Assignee: Silk Therapeutics, Inc.
A61K8/64A45D33/00A61K8/02A61K8/0216A61K8/042A61K8/19A61K8/27A61K8/29A61K8/365A61K8/4953A61K8/676A61K8/735A61K8/922A61K8/97A61K8/987A61K9/08A61K38/00A61K38/012A61Q17/04A61Q19/00A61Q19/007A61Q19/02A61Q19/08C07K1/12C07K14/43586A61K2800/591A61K2800/72A61K2800/74A61K2800/75
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,166,177
App. No.
14/503,076
Granted
Jan 1, 2019
Kind
B2
Abstract

A composition is disclosed that includes pure silk fibroin-based protein fragments that are substantially devoid of sericin, wherein the composition has an average weight average molecular weight ranging from about 17 kDa to about 38 kDa, wherein the composition has a polydispersity of between about 1.5 and about 3.0, wherein the composition is substantially homogeneous, wherein the composition between 0 ppm to about 500 ppm of inorganic residuals, and wherein the composition includes between 0 ppm to about 500 ppm of organic residuals.

Claims (17)

1. A gel comprising a silk protein fragment composition comprising:

pure silk fibroin-based protein fragments substantially devoid of sericin and comprising:

an average weight average molecular weight ranging from about 17 kDa to about 38 kDa; and

a polydispersity of between about 1.5 and about 3.0; and

water,

wherein the composition prior to gelation is a solution which does not spontaneously or gradually gelate and does not visibly change in color or turbidity when in the solution for at least 10 days,

wherein the gel includes between 0 ppm and 500 ppm of inorganic residuals, and

wherein the gel includes between 0 ppm and 500 ppm of organic residuals.

2. The gel of claim 1 , wherein the silk fibroin-based protein fragments comprise between about 1.0% and about 50.0% crystalline protein domains.

3. The gel of claim 1 , wherein the silk protein fragment composition comprises from about 0.5 wt. % to about 8.0 wt. % of pure silk fibroin-based protein fragments.

4. The gel of claim 1 having a pH from about 1.0 to about 7.0.

5. The gel of claim 1 further comprising from about 0.5 wt. % to about 20.0 wt. % of vitamin C or a derivative thereof.

6. The gel of claim 5 wherein the vitamin C or a derivative thereof remains stable within the gel for a period of from about 5 days to about 5 years.

7. The gel of claim 5 wherein the vitamin C or a derivative thereof is stable within the gel so as to result in release of the vitamin C in a biologically active form.

8. The gel of claim 1 further comprising an additive selected from the group consisting of vitamin E, rosemary oil, rose oil, lemon juice, lemon grass oil and caffeine.

9. The gel of claim 1 packaged in an airtight container.

10. The gel of claim 1 wherein the pure silk fibroin-based protein fragments are hypoallergenic.

Assignments (5)
CHANGE OF NAME Recorded Feb 25, 2019
From: SILK, INC.
To: EVOLVED BY NATURE, INC.
Reel/Frame 048423/0276 →
CHANGE OF NAME Recorded Feb 21, 2019
From: SILK THERAPEUTICS, INC.
To: SILK, INC.
Reel/Frame 048407/0364 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2019
From: ALTMAN, GREGORY H.
To: SILK THERAPEUTICS, INC.
Reel/Frame 048371/0301 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2019
From: ALTMAN, GREGORY H.; HORAN, REBECCA L.; DOW, RACHEL LEE; HASS, DYLAN S.; LIND, RACHEL M.
To: SILK THERAPEUTICS, INC.
Reel/Frame 048372/0133 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2019
From: ALTMAN, GREGORY H.; HORAN, REBECCA L.; DOW, RACHEL LEE; HASS, DYLAN S.; LIND, RACHEL M.
To: SILK THERAPEUTICS, INC.
Reel/Frame 048372/0232 →
Continuity (4)
Provisional Application 61884820 · Sep 30, 2013
Provisional Application 62000928 · May 20, 2014
Provisional Application 62036450 · Aug 12, 2014
Related Publication 20150094269A1 · Apr 2, 2015
Cited By (5)
US 12,227,897 US 12,296,067 US 12,385,181 US 12,611,484 US 12,636,250